CA2616717A1 - Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie - Google Patents
Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie Download PDFInfo
- Publication number
- CA2616717A1 CA2616717A1 CA002616717A CA2616717A CA2616717A1 CA 2616717 A1 CA2616717 A1 CA 2616717A1 CA 002616717 A CA002616717 A CA 002616717A CA 2616717 A CA2616717 A CA 2616717A CA 2616717 A1 CA2616717 A1 CA 2616717A1
- Authority
- CA
- Canada
- Prior art keywords
- dna
- virus
- gene
- site
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000010369 molecular cloning Methods 0.000 title claims description 37
- 241000700605 Viruses Species 0.000 title description 386
- 230000001086 cytosolic effect Effects 0.000 title description 63
- 239000013612 plasmid Substances 0.000 claims abstract description 301
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 262
- 239000012634 fragment Substances 0.000 claims abstract description 196
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 193
- 108020004414 DNA Proteins 0.000 description 456
- 210000004027 cell Anatomy 0.000 description 231
- 230000003612 virological effect Effects 0.000 description 162
- 239000013598 vector Substances 0.000 description 142
- 238000010367 cloning Methods 0.000 description 136
- 238000003776 cleavage reaction Methods 0.000 description 117
- 230000007017 scission Effects 0.000 description 117
- 238000003780 insertion Methods 0.000 description 109
- 230000037431 insertion Effects 0.000 description 109
- 238000000034 method Methods 0.000 description 109
- 230000014509 gene expression Effects 0.000 description 108
- 101150106093 gpt gene Proteins 0.000 description 102
- 239000003550 marker Substances 0.000 description 89
- 206010046865 Vaccinia virus infection Diseases 0.000 description 86
- 208000007089 vaccinia Diseases 0.000 description 86
- 238000010276 construction Methods 0.000 description 83
- 241000700662 Fowlpox virus Species 0.000 description 82
- 108091028043 Nucleic acid sequence Proteins 0.000 description 80
- 238000004806 packaging method and process Methods 0.000 description 71
- 108091081024 Start codon Proteins 0.000 description 59
- 102000053602 DNA Human genes 0.000 description 57
- 108020005202 Viral DNA Proteins 0.000 description 47
- 108700026244 Open Reading Frames Proteins 0.000 description 45
- 108091034117 Oligonucleotide Proteins 0.000 description 44
- 239000002299 complementary DNA Substances 0.000 description 41
- 239000000523 sample Substances 0.000 description 39
- 241000588724 Escherichia coli Species 0.000 description 38
- 208000015181 infectious disease Diseases 0.000 description 35
- 101150003725 TK gene Proteins 0.000 description 34
- 108010042407 Endonucleases Proteins 0.000 description 33
- 102000004533 Endonucleases Human genes 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 33
- 238000002105 Southern blotting Methods 0.000 description 31
- 238000013518 transcription Methods 0.000 description 31
- 230000035897 transcription Effects 0.000 description 31
- 108010051456 Plasminogen Proteins 0.000 description 29
- 108091008146 restriction endonucleases Proteins 0.000 description 29
- 210000002845 virion Anatomy 0.000 description 28
- 102100022641 Coagulation factor IX Human genes 0.000 description 27
- 108010076282 Factor IX Proteins 0.000 description 27
- 208000000666 Fowlpox Diseases 0.000 description 27
- 241000287828 Gallus gallus Species 0.000 description 27
- 102000013566 Plasminogen Human genes 0.000 description 27
- 108020004705 Codon Proteins 0.000 description 26
- 238000012217 deletion Methods 0.000 description 26
- 229960004222 factor ix Drugs 0.000 description 26
- 238000012216 screening Methods 0.000 description 26
- 229940096437 Protein S Drugs 0.000 description 25
- 108010066124 Protein S Proteins 0.000 description 25
- 210000001161 mammalian embryo Anatomy 0.000 description 25
- 238000003752 polymerase chain reaction Methods 0.000 description 25
- 230000006798 recombination Effects 0.000 description 25
- 238000005215 recombination Methods 0.000 description 25
- 230000037430 deletion Effects 0.000 description 24
- 210000002950 fibroblast Anatomy 0.000 description 24
- 101150066555 lacZ gene Proteins 0.000 description 24
- 230000004048 modification Effects 0.000 description 22
- 238000012986 modification Methods 0.000 description 22
- 102000029301 Protein S Human genes 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 20
- 230000010076 replication Effects 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 238000013459 approach Methods 0.000 description 19
- 230000002458 infectious effect Effects 0.000 description 19
- 108091026890 Coding region Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 241000725303 Human immunodeficiency virus Species 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000003834 intracellular effect Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 238000012546 transfer Methods 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 15
- 210000004962 mammalian cell Anatomy 0.000 description 15
- 108020004440 Thymidine kinase Proteins 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 239000011543 agarose gel Substances 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- 101710163270 Nuclease Proteins 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 108010047303 von Willebrand Factor Proteins 0.000 description 12
- 102100036537 von Willebrand factor Human genes 0.000 description 12
- 229960001134 von willebrand factor Drugs 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 11
- 238000002703 mutagenesis Methods 0.000 description 11
- 231100000350 mutagenesis Toxicity 0.000 description 11
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 108020005065 3' Flanking Region Proteins 0.000 description 10
- 108020005029 5' Flanking Region Proteins 0.000 description 10
- 241000700629 Orthopoxvirus Species 0.000 description 10
- 108010094028 Prothrombin Proteins 0.000 description 10
- 102100027378 Prothrombin Human genes 0.000 description 10
- 102000006601 Thymidine Kinase Human genes 0.000 description 10
- 230000003321 amplification Effects 0.000 description 10
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 229960000951 mycophenolic acid Drugs 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 229940039716 prothrombin Drugs 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 241000700663 Avipoxvirus Species 0.000 description 9
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 description 9
- 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 description 9
- 241000702208 Shigella phage SfX Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 210000003501 vero cell Anatomy 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 102000052932 human PROS1 Human genes 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 8
- 229940099815 human protein s Drugs 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 7
- 108091029795 Intergenic region Proteins 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 7
- 108090000364 Ligases Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 229960001714 calcium phosphate Drugs 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 7
- 229910000389 calcium phosphate Inorganic materials 0.000 description 7
- 235000011010 calcium phosphates Nutrition 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 229960000027 human factor ix Drugs 0.000 description 7
- 229940039715 human prothrombin Drugs 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000005304 joining Methods 0.000 description 7
- 108010087750 lysyl-plasminogen Proteins 0.000 description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 7
- 241000271566 Aves Species 0.000 description 6
- 241000450599 DNA viruses Species 0.000 description 6
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108700004025 env Genes Proteins 0.000 description 5
- 101150030339 env gene Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282552 Chlorocebus aethiops Species 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 241000701832 Enterobacteria phage T3 Species 0.000 description 4
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010042546 GCGGCCGC-specific type II deoxyribonucleases Proteins 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000013383 initial experiment Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101800001401 Activation peptide Proteins 0.000 description 2
- 102400000069 Activation peptide Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000003682 DNA packaging effect Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 241000701372 Iridovirus Species 0.000 description 2
- 241000726306 Irus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101000626626 Serratia marcescens Type II restriction enzyme SmaI Proteins 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- 102100036860 Troponin T, slow skeletal muscle Human genes 0.000 description 2
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 2
- 241000700646 Vaccinia virus WR Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229960000182 blood factors Drugs 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000020964 regulation of blood coagulation Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- 101710191936 70 kDa protein Proteins 0.000 description 1
- 101150056788 A51R gene Proteins 0.000 description 1
- 108010088237 ATCGAT-specific type II deoxyribonucleases Proteins 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241001473877 Biserrula isolate Species 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 108010037936 CCCGGG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 101150106671 COMT gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 101100457838 Caenorhabditis elegans mod-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000006586 Ectromelia Diseases 0.000 description 1
- 241000725630 Ectromelia virus Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101150111020 GLUL gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 101150106864 HR gene Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010024503 Limb reduction defect Diseases 0.000 description 1
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 1
- 101150110972 ME1 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 241001455645 Rabbitpox virus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 101150082969 SELP gene Proteins 0.000 description 1
- 101150036293 Selenop gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101710109576 Terminal protein Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 101100179982 Xenopus laevis irx1-a gene Proteins 0.000 description 1
- 101100179986 Xenopus tropicalis irx1 gene Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000677 aggregate cell Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 101150014174 calm gene Proteins 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010067298 endodeoxyribonuclease RsrII Proteins 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000007203 infectious ectromelia Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013206 minimal dilution Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000009471 passive packaging Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000700570 unidentified entomopoxvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/750,080 | 1991-08-26 | ||
| US07/750,080 US5445953A (en) | 1991-08-26 | 1991-08-26 | Direct molecular cloning of a modified poxvirus genome |
| US91473892A | 1992-07-20 | 1992-07-20 | |
| US07/914,738 | 1992-07-20 | ||
| CA002558864A CA2558864C (fr) | 1991-08-26 | 1992-08-25 | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002558864A Division CA2558864C (fr) | 1991-08-26 | 1992-08-25 | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2616717A1 true CA2616717A1 (fr) | 1993-02-27 |
Family
ID=39103181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002616717A Abandoned CA2616717A1 (fr) | 1991-08-26 | 1992-08-25 | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie |
| CA2617830A Expired - Fee Related CA2617830C (fr) | 1991-08-26 | 1992-08-25 | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucar otique modifie |
| CA002616698A Expired - Fee Related CA2616698C (fr) | 1991-08-26 | 1992-08-25 | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2617830A Expired - Fee Related CA2617830C (fr) | 1991-08-26 | 1992-08-25 | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucar otique modifie |
| CA002616698A Expired - Fee Related CA2616698C (fr) | 1991-08-26 | 1992-08-25 | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie |
Country Status (1)
| Country | Link |
|---|---|
| CA (3) | CA2616717A1 (fr) |
-
1992
- 1992-08-25 CA CA002616717A patent/CA2616717A1/fr not_active Abandoned
- 1992-08-25 CA CA2617830A patent/CA2617830C/fr not_active Expired - Fee Related
- 1992-08-25 CA CA002616698A patent/CA2616698C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2616698A1 (fr) | 1993-02-27 |
| CA2616698C (fr) | 2009-03-17 |
| CA2617830A1 (fr) | 1993-02-27 |
| CA2617830C (fr) | 2010-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0561034B1 (fr) | Clonage moléculaire direct d'un génome modifié d'un virus chordopox | |
| US5445953A (en) | Direct molecular cloning of a modified poxvirus genome | |
| AU694519B2 (en) | Recombinant poxviruses with foreign polynucleotides in essential regions | |
| JP3044062B2 (ja) | 組換えポックスウイルス宿主選択系 | |
| Falkner et al. | Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors | |
| US5670367A (en) | Recombinant fowlpox virus | |
| Blasco et al. | Selection of recombinant vaccinia viruses on the basis of plaque formation | |
| US5180675A (en) | Recombinant fowlpox virus | |
| KR101005630B1 (ko) | 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는재조합 수두 바이러스 | |
| Scheiflinger et al. | Construction of chimeric vaccinia viruses by molecular cloning and packaging. | |
| US20030013076A1 (en) | Parapoxvirus vectors | |
| EP0753581A1 (fr) | Virus recombinantes eucaryotes cytoplasmiques améliorés, un procédé pour leur préparation et leur utilisation comme vaccins | |
| JPH0365191A (ja) | スフェロイジン単離ｄｎａおよび組み換え昆虫ポックスウィルス発現ベクター | |
| Scheiflinger et al. | Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus | |
| EP0422072B1 (fr) | Procede de selection de virus de la variole recombinants | |
| US5691170A (en) | Generation of hybrid genes and proteins by virus-mediated recombination | |
| EP0469089B1 (fr) | Generation de genes hybrides et de proteines par recombinaison a mediation virale | |
| Mazzara et al. | [39] Generation and analysis of vaccinia virus recombinants | |
| US20040014034A1 (en) | Method of producing a recombinant virus | |
| CA2617830C (fr) | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucar otique modifie | |
| EP0606452A1 (fr) | Vaccins vecteurs d'herpesvirus felin recombine | |
| CA2558864C (fr) | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie | |
| CA2515166C (fr) | Clonage moleculaire direct d'un genome du virus adn cytoplasmique eucaryotique modifie | |
| CZ277921B6 (en) | Peptides and polypeptides, vaccines and nucleic acids | |
| Carroll | Expression analysis and immunogenicity of human immunodeficiency virus type 1 envelope glycoprotein in vaccinia virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |